Add press release announcing Moderna is testing .351 booster candidat…

…e in 60 people
ljl-covid · Mar 11, 2021 · 9c1ce93 · 9c1ce93
1 parent c236022
commit 9c1ce93
Showing 1 changed file with 1 addition and 1 deletion.
diff --git a/README.md b/README.md
@@ -311,7 +311,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine](https://pubmed.ncbi.nlm.nih.gov/33378609/) looks at the results from Moderna's phase 3 [COVE study](https://www.modernatx.com/cove-study) and finds a 94.1% efficacy, with confidence interval from 89.3% to 96.8%, with no severe cases in the vaccine arm, and rare occurrence of serious adverse effects
 * [EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU](https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu) and issues an [opinion with key facts](https://www.ema.europa.eu/en/medicines/human/summaries-opinion/covid-19-vaccine-moderna) including documents about risk management and the produt leaflet
 * [Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa](https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against) as announced in a press release by Moderna, based on a study showing [mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants](https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1), although titers against the South African B.1.351 strain appear much reduced, and the company is studying a "third booster" to address this and potentially other variants
-* [Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine) in a press release issued in February 2021, to address in particular the South African variant, with three possible booster candidate (a variant-specific one, a multivalent one, and a simple third booster of the original vaccine)
+* [Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine) in a press release issued in February 2021, to address in particular the South African variant, with three possible booster candidate (a variant-specific one, a multivalent one, and a simple third booster of the original vaccine), and later in March, [Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-study-evaluating/), with 60 participants to its phase 2 trial additionally receiving one of the booster candidates
 
 #### Pfizer-BioNTech (BNT162b2 or Comirnaty)